201.16
+5.15(+2.63%)
Currency In USD
| Previous Close | 196.01 |
| Open | 195.71 |
| Day High | 203 |
| Day Low | 195 |
| 52-Week High | 216.45 |
| 52-Week Low | 118.03 |
| Volume | 512,498 |
| Average Volume | 416,042 |
| Market Cap | 12.18B |
| PE | -38.32 |
| EPS | -5.25 |
| Moving Average 50 Days | 201.7 |
| Moving Average 200 Days | 172.76 |
| Change | 5.15 |
If you invested $1000 in Ascendis Pharma A/S (ASND) 10 years ago, it would be worth $11,614.32 as of November 12, 2025 at a share price of $201.16. Whereas If you bought $1000 worth of Ascendis Pharma A/S (ASND) shares 5 years ago, it would be worth $1,207.15 as of November 12, 2025 at a share price of $201.16.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism
GlobeNewswire Inc.
Nov 07, 2025 1:30 PM GMT
COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults with hypoparathyroidism treated
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025
GlobeNewswire Inc.
Nov 05, 2025 9:01 PM GMT
COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wednesday, November 12, 2025, after the close of the
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
GlobeNewswire Inc.
Nov 03, 2025 9:01 PM GMT
COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium handling, and continued safety and ef